Galectin-13 and Laeverin Levels Interfere with Human Fetoplacental Growth.
Gal-13
amniotic fluid
fetus
human
laeverin
placenta
serum
sonography
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
08 Jun 2024
08 Jun 2024
Historique:
received:
22
04
2024
revised:
27
05
2024
accepted:
30
05
2024
medline:
27
6
2024
pubmed:
27
6
2024
entrez:
27
6
2024
Statut:
epublish
Résumé
Galectin-13 (Gal-13) is predominantly produced by the syncytiotrophoblast, while laeverin is expressed on the outgrowing extravillous trophoblast, and both are thought to be biomarkers of preeclampsia. The aim of this study was to assess the correlation between concentrations of Gal-13 and laeverin measured in maternal serum and amniotic fluid at 16-22 weeks of gestation and the sonographic assessment of the fetoplacental measurements. Fetal biometric data and placental volume and perfusion indices were measured in 62 singleton pregnancies. Serum and amniotic levels of Gal-13 and laeverin levels were measured using a sandwich ELISA. Both amniotic fluid and serum Gal-13 levels expressed a negative correlation to the plasma laeverin level in mid-pregnancy. Serum laeverin level correlated positively with the gestational length at delivery (β = 0.39,
Identifiants
pubmed: 38928055
pii: ijms25126347
doi: 10.3390/ijms25126347
pii:
doi:
Substances chimiques
Galectins
0
LGALS13 protein, human
0
LVRN protein, human
EC 3.4.-
Biomarkers
0
Pregnancy Proteins
0
Metalloproteases
EC 3.4.-
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM